Heart failure in the elderly

( views:316, downloads:0 )
Author:
Elizabete Viana de Freitas(Department of Cardiology, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Boulevard 28 Setembro, 77 Vila Isabel , Brazil;Department of Geriatrics, Pró-Cardíaco Hospital, Rua General Polidoro 182, Brazil)
Michel Batlouni(Department of Cardiology, Avenida Doutor Arnaldo, 455, Consola(c)(a)o, Sao Paulo, CEP: 01246-000, Brazil;Department of Internal Medicine, Federal University of Goiás, Av. Contorno s/no. Estado: GO Cidade: Gioiania Bairro: Central CEP: 74055-140, Brazil; Department of Cardiology, Dante Pazzanese Institute, Av. Doutor Dante Pazzanese, no 500. Bairro: Ibirapuera/Vila Mariana Cidade: S(a)o Paulo, Braz)
Roberto Gamarsky(Department of Geriatrics, Pró-Cardíaco Hospital, Rua General Polidoro 182, Brazil;Department of Geriatrics, Federal University of Rio de Janeiro, RJ 20551-030 , Brazil)
Journal Title:
JOURNAL OF GERIATRIC CARDIOLOGY
Issue:
Volume 09, Issue 02, 2012
DOI:
10.3724/SP.J.1263.2011.12295
Key Word:
Elderly people;Geriatric problens;Heart failure;Hypertension

Abstract: The aging of the population is, currently, a major phenomenon, drawing the attention of a number of investigators. The significant increase of life expectancies over the past few decades, in addition to social and economic consequences, has lead to a major change in the morbidity and mortality profile of elders. Heart failure (HF) is a condition in which the heart can not pump enough blood to meet the body's needs. HF is predominantly a disorder of the elderly with rates increasing exponentially. The prevalence of HF approximately doubles with each decade of life. As people live longer, the occurrence of HF rises, as well as other conditions that complicate its treatment. Impaired heart function implies a reduced duration of survival. Fortunately, many factors that can prevent HF and improve outcome are known and can be applied at any stage. This review emphasizes the importance of factors inherent in aging itself, focusing on heart disease, particularly as a disease of aging, can help critically refine management of this acute and chronic disease, as well as foster preventive strategies to reduce the incidence of this common malady.

  • [1]Ho KK,Pinsky JL,Kannel WB,et al.The epidemiology of heart failure:The Framingham Study.J Am Coll Cardiol 1993;22(4 Suppl A):6A–13A.
  • [2]Kannel WB,Ho K,Thom T.Changing epidemiological features of cardiac failure.Br Heart J 1994;72(2 Suppl):S3–S9.
  • [3]Petrie MC,Berry C,Stewart S,et al.Failing aging hearts.Eur Heart J 2001;22:1978–1990.
  • [4]Weir RAP,Mcmurray JJV,Taylor J,et al.Heart failure in older patients.Br J Cardiol 2006;13:257–266.
  • [5]Abdelhafz AH.Heart failure in older people:causes,diagnosis and treatment.Age Ageing 2002;31:29–36.
  • [6]Gillespie ND.The diagnosis and management of chronic heart failure in older patient.Br Med Bull 2006;75–76:49–62.
  • [7]Wenger NK.Cardiovascular disease in the elderly.Curr Probl Cardiol 1992;17:611–690.
  • [8]Rich MW.Heart failure:Epidemiology,Pathophysiology and Management.In Cardiovascular Disease in the Octogenarium and Beyond;Wenger NK,Ed;Martin Dunitz:London,UK,1999;73–91.
  • [9]Gravina CF,Rosa RF,Franken RA,et al.Guidelines in Cardiogeriatrics II of the Brazilian Society of Cardiology.Arq Bras Cardiol 2010;95(Supl.2):S1–S112.
  • [10]Franklin SS,Gustin W,Wong ND,et al.Hemodynamic patterns of age-related changes in blood pressure.The Framingham Heart Study.Circulation 1997;96:308–315.
  • [11]Paulus Wj,Tsch(o)pe C,Sanderson JE,et al.How to diagnose diastolic heart failure:a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by Heart Failure and Echocardiography Associations of the European Society of Cardiology.Eur Heart J 2007;28:2539–2550.
  • [12]Haney S,Sur D,Xu Z.Diastolic heart failure.A review and primary care perspective.J Am Board Fam Med 2005;18:189–198.
  • [13]Batlouni M,Freitas EV,Neto Savioli F.Heart Failure in the Elderly.In Treaty of Geriatrics and Gerontology;3rd Edition;Freitas EV,Py L,Eds.;Rio de Janeiro:Brazil 2011;462–483.
  • [14]Batlouni M,Savioli Neto F,Magalh(a)es HM.Altera(c)(o)es Farmacocinéticas e Farmacodinamicas Relacionadas à Idade.Terapêutica Cardiovascular no Idoso.In Farmacologia e Terapêutica Cardiovascular;Batlouni M,Ramires JAF,Eds.;S(a)o Paulo:Atheneu 1999:27–46.
  • [15]Swedberg K,Cleland J,Dargie H,et al.Guidelines for the diagnosis and treatment of chronic heart failure:executive summary (update 2005):the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology.Eur Heart J 2005;26:1115–1140.
  • [16]Davie AP,Francis CM,Love MP,et al.Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction.Br Med J 1996;312:222–227.
  • [17]A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).Circulation 2005;112:1825–1852.
  • [18]The RALES Investigators.Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study–RALES).Am J Cardiol 1996;78:902–907.
  • [19]Goldsmith S,Marx S.Update use of digitalis and nitrates in the elderly.Geriatrics 1988:43:71–76.
  • [20]The effect of digoxin on mortality and morbidity in patients with heart failure.The Digitails Investigation Group.N Engl J Med 1997;336:525–533.
  • [21]Schwartz S,Zipes DP.Cardiovascular disease in special populations.In Treaty of Cardiovascular Disease;Zipes DP,Libby P,Bonow R,et al.,Eds;Saunders:New York,2006;1925–1949.
  • [22]Cohn JN,Archibald DG,Ziesche S,et al.Effect of vasodilator therapy on mortality in chronic congestive heart failure.Results of a Veterans Administration Cooperative Study.N Engl J Med 1986;314:1547–1552.
  • [23]McMurray JJ,Young JB,Dunlap ME,et al.CHARM Investigators.Relationship of dose of background angiotensinconverting enzyme inhibitor to the benefits of candesartan in the Candesartan in heart failure:Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.Am Heart J 2006;151:985–991.
  • [24]Merit-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF).Lancet 1999;94:2807–2816.
  • [25]Packer M,Coats AJS,Fowler MB,et al.Effect of carvedilol in severe chronic heart failure.New Engl J Med 1996;334;1349–1355.
  • [26]CIBIS II Investigators and Committies.The Cardiac insufficiency Bisoprol Study:A randodomized trial.Lancet 1999;353:9–13.
  • [27]Flather MD,Shibata MC,Coats AJ,et al.Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).Eur Heart J 2005;26:215–225.
  • [28]Leclercq C,Kass DA.Retiming the failing heart:principles and current clinical status of cardiac resynchronization.J Am Coll Cardiol 2002;39:194.
  • [29]Setaro JF,Zaret BL,Schulman DS,et al.Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.Am J Cardiol 1990;66:981–986.
  • [30]Warner JG Jr.,Metzger DC,Kitzman DW,et al.Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.J Am Coll Cardiol 1999;33:1567-1572.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn